Veeva Systems (VEEV) is drawing attention as the company prepares to report second quarter results on August 26, 2026, following a recent session where the stock moved ahead of major market indices.
See our latest analysis for Veeva Systems.
For context, Veeva Systems has shown strong recent share price momentum, with a 30-day share price return of 13.26% and a 90-day share price return of 30.94%, even though the year to date share price return is slightly down and the 1-year total shareholder return is down 22.15%.
If Veeva’s earnings update has you watching software and data driven healthcare companies more closely, it could be a useful time to scan a wider field through the 42 healthcare AI stocks
The recent rebound in Veeva Systems, alongside a discount of about 12% to the average analyst price target and an estimated 28% intrinsic discount, sets up a straightforward question: Is the market being careful or too cautious on this stock?
Most Popular Narrative: 31.9% Undervalued
At a last close of $217.80 against a fair value estimate of $320.00, the leading narrative on Veeva Systems argues that the current price leaves a sizable gap to intrinsic value and places the focus firmly on the strength of the core business and its AI optionality.
Veeva is not simply another cloud-software company selling productivity tools. It has built deeply embedded software across the life-sciences value chain: clinical trials, regulatory submissions, drug safety, quality, medical affairs, and commercial operations. Its systems sit close to the operational core of pharmaceutical and biotechnology companies.
Curious what kind of earnings profile and margin structure sit behind a fair value well above today’s share price? The narrative leans on a mix of recurring revenue, disciplined profitability and assumptions about how AI products could deepen Veeva Systems’ role in regulated workflows. The details matter. The full story shows how those pieces fit together into the $320.00 fair value view.
Result: Fair Value of $320.00 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Veeva Systems still faces real risks, including slower spending after large pharma mergers and the chance that Falcon adoption or pricing falls short of bullish expectations.
Find out about the key risks to this Veeva Systems narrative.
Another View: What Veeva Systems’ P/E Is Telling You
On earnings power, Veeva Systems looks attractive. The stock trades about 28.2% below the Simply Wall St fair value estimate, and at $217.80 is also below the modelled future cash flow value of $303.42 per share.
The picture changes when you look at the P/E. Veeva Systems trades on 37.6x earnings, which is higher than the Global Healthcare Services industry average of 26.7x and above the 31x fair ratio that the market could eventually move towards. That premium can reflect quality, but it also means less room for error if growth or AI monetisation disappoints. Which signal do you treat as more important right now: the discounted cash flow or the rich earnings multiple?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
This mix of optimism and caution around Veeva Systems creates a clear decision point for you as an investor. Act while the current debate is fresh and review the 3 key rewards
Looking for more investment ideas beyond Veeva Systems?
If you stop with Veeva Systems, you risk missing other compelling setups. Use the Simply Wall St screener tools to widen your opportunity set before the next move.
- Spot potential income anchors for your portfolio and review 9 dividend fortresses that prioritise generous yields with a focus on resilience.
- Hunt for quality at a discount by scanning the screener containing 19 high quality undiscovered gems that the broader market may not be watching yet.
- Strengthen your defensive core and check the solid balance sheet and fundamentals stocks screener (49 results) to find companies backed by sturdier financial foundations.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com